<DOC>
	<DOCNO>NCT01656148</DOCNO>
	<brief_summary>Fampridine-SR register treatment walk incapacity MS patient . Two pivotal trial show app . 40 % MS patient walk incapacity improve walk speed averagely 25 % recieving drug . This show use Timed 25 Foot Walk Test ( T25FW ) . No effect cognition upper limb function show , investigated patient respond drug measure abovementioned test . The question case also another walk test , term Six Spot Step Test ( SSST ) , sensitive effect Fampridine-SR. Primary outcome measure effect measure SSST . The hypothesis SSST less sensitive effect Fampridine-SR T25FW .</brief_summary>
	<brief_title>FAME - Fampyra Outcome Measures Study : Study Different Outcome Measures Effect Fampyra</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>Patients clinically definite multiple sclerosis diagnose accord McDonald criterion EDSS 47 Pyramidal FS &gt; = 2 History epileptic seizure MS relapse change disease modify treatment ( DMT ) within 60 day cancer within five year uncontrolled hypertension clinically important cardiac , hepatic , renal pulmonary disease pregnancy breast feed concomitant treatment cimetidine , carvedilol , propranolol metformin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Multiple sclerosis</keyword>
	<keyword>Walking disablility</keyword>
	<keyword>Mobility</keyword>
	<keyword>Six Spot Step Test</keyword>
	<keyword>Outcome measure</keyword>
	<keyword>Fampridine-SR</keyword>
	<keyword>Fampyra</keyword>
</DOC>